Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Jul;158(1):195-205.
doi: 10.1016/j.chest.2020.03.032. Epub 2020 Mar 26.

Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1

Affiliations
Comparative Study

Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1

Xiao Tang et al. Chest. 2020 Jul.

Abstract

Background: Since the outbreak of coronavirus disease 2019 (COVID-19) in China in December 2019, considerable attention has been focused on its elucidation. However, it is also important for clinicians and epidemiologists to differentiate COVID-19 from other respiratory infectious diseases such as influenza viruses.

Research question: The aim of this study was to explore the different clinical presentations between COVID-19 and influenza A (H1N1) pneumonia in patients with ARDS.

Study design and methods: This analysis was a retrospective case-control study. Two independent cohorts of patients with ARDS infected with either COVID-19 (n = 73) or H1N1 (n = 75) were compared. Their clinical manifestations, imaging characteristics, treatments, and prognosis were analyzed and compared.

Results: The median age of patients with COVID-19 was higher than that of patients with H1N1, and there was a higher proportion of male subjects among the H1N1 cohort (P < .05). Patients with COVID-19 exhibited higher proportions of nonproductive coughs, fatigue, and GI symptoms than those of patients with H1N1 (P < .05). Patients with H1N1 had higher Sequential Organ Failure Assessment (SOFA) scores than patients with COVID-19 (P < .05). The Pao2/Fio2 of 198.5 mm Hg in the COVID-19 cohort was significantly higher than the Pao2/Fio2 of 107.0 mm Hg in the H1N1 cohort (P < .001). Ground-glass opacities was more common in patients with COVID-19 than in patients with H1N1 (P < .001). There was a greater variety of antiviral therapies administered to COVID-19 patients than to H1N1 patients. The in-hospital mortality of patients with COVID-19 was 28.8%, whereas that of patients with H1N1 was 34.7% (P = .483). SOFA score-adjusted mortality of H1N1 patients was significantly higher than that of COVID-19 patients, with a rate ratio of 2.009 (95% CI, 1.563-2.583; P < .001).

Interpretation: There were many differences in clinical presentations between patients with ARDS infected with either COVID-19 or H1N1. Compared with H1N1 patients, patients with COVID-19-induced ARDS had lower severity of illness scores at presentation and lower SOFA score-adjusted mortality.

Keywords: ARDS; COVID-19; H1N1; influenza A; mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A-D, Imaging characteristics of chest CT scans from patients with coronavirus disease 2019 (COVID-19) and influenza A (H1N1) . A, A 60-year-old man with COVID-19 exhibited multiple ground-glass opacities in both lungs. B, A 75-year-old man with COVID-19 exhibited diffuse ground-glass opacities in both lungs. C, A 46-year-old woman with H1N1 exhibited exudation and consolidation distributed with bronchus in multiple lobes and segments. D, A 66-year-old man with H1N1 exhibited ground-glass opacities with little exudation and consolidation distributed diffusely in both lungs.
Figure 2
Figure 2
Multivariate model of the specific risk factors for COVID-19 or H1N1. Plots reporting variables independently associated with the risk for COVID-19 or H1N1 in the final model, with their 95% CIs. APACHE = Acute Physiology and Chronic Health Evaluation; AST = aspartate transaminase; SOFA = sequential organ failure assessment. See Figure 1 legend for expansion of other abbreviations.

References

    1. Wenjie T., Xiang Z., Xuejun M. A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019−2020. China CDC Weekly. 2020;2(4):61–62. - PMC - PubMed
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Li Q., Guan X., Wu P. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. - PMC - PubMed
    1. World Health Organization Coronavirus disease (COVID-2019) situation reports-50. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio...
    1. Iuliano A.D., Roguski K.M., Chang H.H. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300. - PMC - PubMed

Publication types

MeSH terms

Substances